MiNK Therapeutics, Inc. INKT 深 沪
已收盘 11-06 16:00:00 美东时间
10.35
+0.300
+2.99%
华盛通- 最 高10.88
- 今 开9.82
- 成交量 7674股
- 最 低 9.82
- 昨 收 10.05
- 总市值 5281.61万
- 52周最高 16.9267
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 8.4801
- 委 比 -76.19%
- 总股本 510.30万
- 历史最高 221.55
- 量 比 0.76
- 振 幅 10.55%
- 历史最低 4.5601
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩上调AMD目标价至725美元；安进、多邻国绩后获华尔街大行看多
今日重点评级关注：康托·菲茨杰拉德：维持Supernus"超配"评级，目标价从67美元升至87美元；丰业银行：维持Atlas Energy Solutions"跑赢大市"评级，目标价从17美元升至18美元
11-05 14:06
HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38
HC Wainwright & Co. analyst Matthew Keller assumes MiNK Therapeutics (NASDAQ:INKT) with a Buy rating and announces Price Target of $38.
11-05 02:21
美股大行评级 | 潜在涨幅227.21%！Jones Trading上调Rapport Therapeutics(RAPP)目标价至82美元，维持"买入"评级
今日重点评级关注：Jones Trading：维持Rapport Therapeutics"买入"评级，目标价从50美元升至82美元；摩根大通：维持SpaceX"超配"评级，目标价从240美元升至500美元
10-22 11:59
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50
B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.
10-21 22:33
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of $(1.06) per share from the same period last year.
08-13 19:32
MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical Illness
First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class immune
05-28 21:07
MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases
05-20 23:10
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call
MiNK Therapeutics (NASDAQ:INKT) held its first-quarter earnings conference call...
05-15 21:46
MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 18.57 percent increase over losses of $(0.70) per share from
05-15 19:36
